Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
1(6%)
Results Posted
31%(4 trials)
Terminated
1(6%)

Phase Distribution

Ph not_applicable
1
6%
Ph phase_4
2
13%
Ph phase_2
3
19%
Ph phase_1
10
63%

Phase Distribution

10

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
10(62.5%)
Phase 2Efficacy & side effects
3(18.8%)
Phase 4Post-market surveillance
2(12.5%)
N/ANon-phased studies
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

13 of 15 finished

Non-Completion Rate

13.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(13)
Terminated(2)

Detailed Status

Completed13
Withdrawn1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Phase 110 (62.5%)
Phase 23 (18.8%)
Phase 42 (12.5%)
N/A1 (6.3%)

Trials by Status

withdrawn16%
completed1381%
recruiting16%
terminated16%

Recent Activity

1 active trials
Showing 5 of 16
completedphase_1

Phase Ib of L-NMMA and Pembrolizumab

NCT03236935
recruitingphase_2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

NCT05660083
completedphase_1

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

NCT02834403
completedphase_2

Niacin to Improve Blood Flow in People With Sickle Cell Disease

NCT00508989
terminatedphase_1

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

NCT00327080
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT03236935Phase 1

Phase Ib of L-NMMA and Pembrolizumab

Completed
NCT05660083Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Recruiting
NCT02834403Phase 1

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Completed
NCT00508989Phase 2

Niacin to Improve Blood Flow in People With Sickle Cell Disease

Completed
NCT00327080Phase 1

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

Terminated
NCT00072826Phase 1

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

Completed
NCT00095472Phase 1

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

Completed
NCT03066115Phase 1

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

Withdrawn
NCT01701973Phase 4

Effect of DPP4 Inhibition on Growth Hormone Secretion

Completed
NCT01122407Phase 1

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Completed
NCT00690534Phase 1

Insulin and Sarcopenia in the Elderly

Completed
NCT01744236Phase 4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Completed
NCT00178919Not Applicable

Nitric Oxide and the Autonomic Nervous System

Completed
NCT00185003Phase 1

Blockade of Vascular Potassium Channels During Human Endotoxemia

Completed
NCT00076414Phase 1

The Effect of Lopinavir/Ritonavir on Endothelial Function

Completed
NCT00009581Phase 2

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16